Squarepoint’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.7M | Buy |
1,705,829
+1,436,527
| +533% | +$20.6M | 0.03% | 590 |
|
|
2025
Q4 | $3.83M | Buy |
269,302
+210,328
| +357% | +$2.07M | ﹤0.01% | 1626 |
|
|
2025
Q3 | $465K | Sell |
58,974
-859,911
| -94% | -$6.12M | ﹤0.01% | 3305 |
|
|
2025
Q2 | $5.27M | Sell |
918,885
-621,037
| -40% | -$4.01M | 0.01% | 1428 |
|
|
2025
Q1 | $12.6M | Buy |
1,539,922
+122,770
| +9% | +$1.14M | 0.02% | 921 |
|
|
2024
Q4 | $13.3M | Buy |
1,417,152
+753,060
| +113% | +$7.83M | 0.01% | 983 |
|
|
2024
Q3 | $7.09M | Buy |
664,092
+13,537
| +2% | +$147K | 0.01% | 1187 |
|
|
2024
Q2 | $6.45M | Buy |
650,555
+399,449
| +159% | +$4.1M | 0.01% | 1205 |
|
|
2024
Q1 | $2.96M | Buy |
+251,106
| New | +$3.21M | 0.01% | 1835 |
|
|
2023
Q4 | – | Sell |
-123,919
| Closed | -$1.51M | – | 4155 |
|
|
2023
Q3 | $1.51M | Buy |
123,919
+106,598
| +615% | +$1.38M | ﹤0.01% | 2027 |
|
|
2023
Q2 | $218K | Buy |
17,321
+4,986
| +40% | +$59.2K | ﹤0.01% | 3168 |
|
|
2023
Q1 | $137K | Buy |
+12,335
| New | +$152K | ﹤0.01% | 2908 |
|
|
2022
Q3 | – | Sell |
-12,500
| Closed | -$134K | – | 3139 |
|
|
2022
Q2 | $134K | Buy |
+12,500
| New | +$103K | ﹤0.01% | 2577 |
|
|
2021
Q4 | – | Sell |
-46,259
| Closed | -$442K | – | 3272 |
|
|
2021
Q3 | $442K | Buy |
46,259
+14,960
| +48% | +$153K | ﹤0.01% | 2029 |
|
|
2021
Q2 | $302K | Sell |
31,299
-500,312
| -94% | -$4.88M | ﹤0.01% | 2526 |
|
|
2021
Q1 | $5.25M | Buy |
+531,611
| New | +$8.23M | 0.03% | 608 |
|
|
2020
Q2 | – | Sell |
-112,795
| Closed | -$1.04M | – | 2315 |
|
|
2020
Q1 | $1.04M | Buy |
+112,795
| New | +$1.07M | 0.03% | 704 |
|
|
2019
Q4 | – | Sell |
-143,942
| Closed | -$1.15M | – | 2578 |
|
|
2019
Q3 | $1.15M | Sell |
143,942
-20,793
| -13% | -$226K | 0.01% | 1133 |
|
|
2019
Q2 | $2.06M | Sell |
164,735
-117,370
| -42% | -$1.49M | 0.02% | 831 |
|
|
2019
Q1 | $3.84M | Buy |
282,105
+248,829
| +748% | +$3.04M | 0.04% | 536 |
|
|
2018
Q4 | $319K | Sell |
33,276
-104,124
| -76% | -$1.14M | ﹤0.01% | 1477 |
|
|
2018
Q3 | $1.66M | Buy |
137,400
+51,480
| +60% | +$720K | 0.02% | 788 |
|
|
2018
Q2 | $1.34M | Sell |
85,920
-46,299
| -35% | -$700K | 0.02% | 777 |
|
|
2018
Q1 | $1.99M | Buy |
132,219
+76,478
| +137% | +$1.16M | 0.03% | 578 |
|
|
2017
Q4 | $802K | Buy |
55,741
+34,689
| +165% | +$477K | 0.01% | 932 |
|
|
2017
Q3 | $317K | Buy |
+21,052
| New | +$278K | 0.01% | 1154 |
|
|
2017
Q2 | – | Sell |
-48,095
| Closed | -$343K | – | 1616 |
|
|
2017
Q1 | $343K | Sell |
48,095
-20,072
| -29% | -$127K | 0.01% | 1027 |
|
|
2016
Q4 | $339K | Buy |
68,167
+43,667
| +178% | +$302K | 0.01% | 1073 |
|
|
2016
Q3 | $181K | Buy |
+24,500
| New | +$165K | 0.01% | 909 |
|
|
2016
Q2 | – | Sell |
-83,600
| Closed | -$706K | – | 1187 |
|
|
2016
Q1 | $706K | Buy |
83,600
+42,200
| +102% | +$299K | 0.05% | 486 |
|
|
2015
Q4 | $401K | Buy |
41,400
+200
| +0.5% | +$1.8K | 0.04% | 653 |
|
|
2015
Q3 | $576K | Buy |
+41,200
| New | +$646K | 0.14% | 178 |
|
|
2015
Q1 | – | Sell |
-51,479
| Closed | -$428K | – | 446 |
|
|
2014
Q4 | $428K | Buy |
+51,479
| New | +$353K | 0.41% | 92 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Squarepoint's FOLD Position: Q1 2026 in Review
Squarepoint increased its Amicus Therapeutics (FOLD) stake by 533% in Q1 2026, buying an estimated $20.6M and bringing the position to 1,705,829 shares worth $24.7M. The position accounts for 0.03% of the portfolio, ranked #590.
Squarepoint first reported a position in FOLD in Q4 2014 and has held it in 33 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Squarepoint held 1,705,829 shares of Amicus Therapeutics worth $24.7M as of Q1 2026.
- Squarepoint bought 1,436,527 Amicus Therapeutics shares in Q1 2026, an estimated $20.6M.
- Amicus Therapeutics made up 0.03% of Squarepoint's portfolio in Q1 2026, its #590 holding.
- Squarepoint first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 33 quarters since.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.